Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Cel-Sci Corp (NY: CVM ) 0.8730 -0.0168 (-1.89%) Official Closing Price Updated: 8:00 PM EDT, Nov 1, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 188,044 Open 0.8917 Bid (Size) 0.8701 (9) Ask (Size) 0.9100 (1) Prev. Close 0.8898 Today's Range 0.8700 - 0.9170 52wk Range 0.8700 - 3.230 Shares Outstanding 61,493,229 Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News FDA’s Oncologic Drugs Advisory Committee Decision on Checkpoint Inhibitors Substantiates Potential of CEL-SCI’s Multikine® to Address Major Treatment Gap for PD-L1 Negative Cancer Patients October 22, 2024 From CEL-SCI Corporation Via Business Wire CEL-SCI Selects Ergomed as CRO as it Gears Up for Confirmatory FDA Registration Study of Multikine® in Head and Neck Cancer October 01, 2024 From CEL-SCI Corporation Via Business Wire Performance YTD -67.55% -67.55% 1 Month -19.17% -19.17% 3 Month -23.42% -23.42% 6 Month -49.24% -49.24% 1 Year -62.53% -62.53% More News Read More CEL-SCI’s Multikine® Increased 5-Year Survival Rate to 82.6% in Locally Advanced Resectable Head & Neck Cancer Patients Who Were Deemed to be in the Treatment Group for Surgery and Radiation September 16, 2024 From CEL-SCI Corporation Via Business Wire CVM Stock Earnings: CEL-SCI Misses EPS for Q3 2024 August 16, 2024 Via InvestorPlace CEL-SCI to Present New Data for Multikine® Head & Neck Cancer Immunotherapy at the European Society for Medical Oncology 2024 Congress September 10, 2024 From CEL-SCI Corporation Via Business Wire The UK’s Medicines & Healthcare Products Regulatory Agency Grants CEL-SCI a Pediatric Waiver, Bringing Multikine® One Step Closer to Future Marketing Clearance September 04, 2024 From CEL-SCI Corporation Via Business Wire CEL-SCI Corporation Reports Third Quarter Fiscal 2024 Financial Results August 15, 2024 From CEL-SCI Corporation Via Business Wire CVM Stock Earnings: CEL-SCI Reported Results for Q2 2024 May 16, 2024 Via InvestorPlace BioMedNewsBreaks — CEL-SCI Corp. (NYSE American: CVM) Closes on $10.8M Best-Efforts Offering August 02, 2024 Via Investor Brand Network Exposures Product Safety CEL-SCI Announces Closing of $10.8 Million Offering July 29, 2024 From CEL-SCI Corporation Via Business Wire CEL-SCI Announces Pricing of $10.8 Million Offering July 26, 2024 From CEL-SCI Corporation Via Business Wire Why Saia Shares Are Trading Lower? Here Are Other Stocks Moving In Friday's Mid-Day Session July 26, 2024 Via Benzinga CEL-SCI’s Phase 3 Population Analysis for Upcoming Confirmatory Registration Study in Head & Neck Cancer Demonstrates Well Balanced Patient Population, Confidence in Clinical Results July 26, 2024 From CEL-SCI Corporation Via Business Wire CEL-SCI Appoints Robert Watson as Chairperson of the Board July 08, 2024 From CEL-SCI Corporation Via Business Wire CEL-SCI Presents Head & Neck Cancer Data at Iddst Annual Congress in Budapest: Risk of Death Cut in Half for Patients Treated With Multikine in the Target Population June 18, 2024 From CEL-SCI Corporation Via Business Wire Dr. Giovanni Selvaggi, Who Has Brought Several Oncology Drugs to Market, Joins CEL-SCI as Clinical Advisor June 06, 2024 From CEL-SCI Corporation Via Business Wire CEL-SCI Corporation Reports Second Quarter Fiscal 2024 Financial Results May 16, 2024 From CEL-SCI Corporation Via Business Wire 12 Health Care Stocks Moving In Thursday's Pre-Market Session May 09, 2024 Via Benzinga Why CEL-SCI (CVM) Shares Are Trading Higher May 08, 2024 Via Benzinga Exposures Product Safety CEL-SCI Receives FDA Go-Ahead for Its Confirmatory Study of Multikine in the Treatment of Head & Neck Cancer May 08, 2024 From CEL-SCI Corporation Via Business Wire 12 Health Care Stocks Moving In Wednesday's Pre-Market Session May 08, 2024 Via Benzinga CEL-SCI Appoints Mario Gobbo to Its Board of Directors April 23, 2024 From CEL-SCI Corporation Via Business Wire CEL-SCI’s LEAPS Vaccine Offers Promising New Paradigm to Treat Rheumatoid Arthritis: Published in Frontiers in Immunology March 19, 2024 From CEL-SCI Corporation Via Business Wire CEL-SCI Corporation Issues Letter to Shareholders March 06, 2024 From CEL-SCI Corporation Via Business Wire CEL-SCI Corporation Reports First Quarter Fiscal 2024 Financial Results February 15, 2024 From CEL-SCI Corporation Via Business Wire Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
